These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

657 related items for PubMed ID: 33482745

  • 1. Diagnostic accuracy of a liquid chromatography-tandem mass spectrometry assay in small hair samples for rifampin-resistant tuberculosis drug concentrations in a routine care setting.
    Metcalfe J, Bacchetti P, Esmail A, Reckers A, Aguilar D, Wen A, Huo S, Muyindike WR, Hahn JA, Dheda K, Gandhi M, Gerona R.
    BMC Infect Dis; 2021 Jan 22; 21(1):99. PubMed ID: 33482745
    [Abstract] [Full Text] [Related]

  • 2. Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples.
    Reckers A, Wen A, Aguilar D, Bacchetti P, Gandhi M, Metcalfe J, Gerona R.
    J Vis Exp; 2020 May 19; (159):. PubMed ID: 32510502
    [Abstract] [Full Text] [Related]

  • 3. A battery of tandem mass spectrometry assays with stable isotope-dilution for the quantification of 15 anti-tuberculosis drugs and two metabolites in patients with susceptible-, multidrug-resistant- and extensively drug-resistant tuberculosis.
    Mercier T, Desfontaine V, Cruchon S, Da Silva Pereira Clara JA, Briki M, Mazza-Stalder J, Kajkus A, Burger R, Suttels V, Buclin T, Opota O, Koehler N, Sanchez Carballo PM, Lange C, André P, Decosterd LA, Choong E.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Nov 15; 1211():123456. PubMed ID: 36240540
    [Abstract] [Full Text] [Related]

  • 4. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda.
    Kabahita JM, Kabugo J, Kakooza F, Adam I, Guido O, Byabajungu H, Namutebi J, Namaganda MM, Lutaaya P, Otim J, Kakembo FE, Kanyerezi S, Nabisubi P, Sserwadda I, Kasule GW, Nakato H, Musisi K, Oola D, Joloba ML, Mboowa G.
    Antimicrob Resist Infect Control; 2022 May 12; 11(1):68. PubMed ID: 35550202
    [Abstract] [Full Text] [Related]

  • 5. A Bedaquiline, Pyrazinamide, Levofloxacin, Linezolid, and Clofazimine Second-line Regimen for Tuberculosis Displays Similar Early Bactericidal Activity as the Standard Rifampin-Based First-line Regimen.
    Zainabadi K, Vilbrun SC, Mathurin LD, Walsh KF, Pape JW, Fitzgerald DW, Lee MH.
    J Infect Dis; 2024 Aug 16; 230(2):e447-e456. PubMed ID: 38060827
    [Abstract] [Full Text] [Related]

  • 6. Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography-electrospray ionization-tandem mass spectrometry.
    Kim HJ, Seo KA, Kim HM, Jeong ES, Ghim JL, Lee SH, Lee YM, Kim DH, Shin JG.
    J Pharm Biomed Anal; 2015 Jan 16; 102():9-16. PubMed ID: 25218029
    [Abstract] [Full Text] [Related]

  • 7. Quantifying Isoniazid Levels in Small Hair Samples: A Novel Method for Assessing Adherence during the Treatment of Latent and Active Tuberculosis.
    Gerona R, Wen A, Chin AT, Koss CA, Bacchetti P, Metcalfe J, Gandhi M.
    PLoS One; 2016 Jan 16; 11(5):e0155887. PubMed ID: 27191185
    [Abstract] [Full Text] [Related]

  • 8. Simultaneous analysis of 11 medications for drug resistant TB in small hair samples to quantify adherence and exposure using a validated LC-MS/MS panel.
    Gerona R, Wen A, Aguilar D, Shum J, Reckers A, Bacchetti P, Gandhi M, Metcalfe J.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Sep 01; 1125():121729. PubMed ID: 31369929
    [No Abstract] [Full Text] [Related]

  • 9. Variation in missed doses and reasons for discontinuation of anti-tuberculosis drugs during hospital treatment for drug-resistant tuberculosis in South Africa.
    Pietersen E, Anderson K, Cox H, Dheda K, Bian A, Shepherd BE, Sterling TR, Warren RM, van der Heijden YF.
    PLoS One; 2023 Sep 01; 18(2):e0281097. PubMed ID: 36780443
    [Abstract] [Full Text] [Related]

  • 10. Plasma drug activity assay for treatment optimization in tuberculosis patients.
    Heysell SK, Mtabho C, Mpagama S, Mwaigwisya S, Pholwat S, Ndusilo N, Gratz J, Aarnoutse RE, Kibiki GS, Houpt ER.
    Antimicrob Agents Chemother; 2011 Dec 01; 55(12):5819-25. PubMed ID: 21968363
    [Abstract] [Full Text] [Related]

  • 11. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK, Kim JH, Kang H, Cho JS, Smego RA.
    Int J Infect Dis; 2009 Mar 01; 13(2):170-5. PubMed ID: 18768342
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
    Schnippel K, Berhanu RH, Black A, Firnhaber C, Maitisa N, Evans D, Sinanovic E.
    BMC Infect Dis; 2016 Oct 21; 16(1):593. PubMed ID: 27769174
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp L, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM.
    Lancet; 2015 May 02; 385(9979):1738-1747. PubMed ID: 25795076
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic drug monitoring in the treatment of tuberculosis.
    Peloquin CA.
    Drugs; 2002 May 02; 62(15):2169-83. PubMed ID: 12381217
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The Changing Paradigm of Drug-Resistant Tuberculosis Treatment: Successes, Pitfalls, and Future Perspectives.
    Dookie N, Ngema SL, Perumal R, Naicker N, Padayatchi N, Naidoo K.
    Clin Microbiol Rev; 2022 Dec 21; 35(4):e0018019. PubMed ID: 36200885
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.